EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Long-Acting Growth Hormone for Pediatric Growth Hormone Deficiency

Norbert Albers, Sarah Cadarette iD, Ben Feakins, María Arregui, Stephen Ebohon, Pamela Lai, Subhara Raveendran, Mads Kjelgaard-Hansen, Christine Andersen, Carol Zhao, Alden Smith, Mitchell Geffner

Journal of the Endocrine Society · 24.03.2025 · 9 (5)

DOI: 10.1210/jendso/bvaf040 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the Endocrine Society, online erschienen am 04.03.2025. Verfasst von Norbert Albers und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Endocrinology, Christliches Kinderhospital, Osnabrueck 49074, Germany. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ascendis Pharma A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Long-acting growth hormone (LAGH) has the potential to improve adherence and outcomes over daily somatropin in growth hormone deficiency (GHD). Whereas daily somatropin products are molecularly identical, LAGHs are molecularly distinct; additional moieties or mechanisms that prolong LAGH action confer unique pharmacodynamic/pharmacokinetic properties that could affect efficacy and safety. Only one LAGH available in the United States and Europe (lonapegsomatropin) delivers unmodified somatropin. With no head-to-head clinical trials of LAGHs available, this systematic literature review and network meta-analysis were conducted to compare the relative efficacy and safety of LAGHs in pediatric GHD. Five trials were eligible for inclusion in a Bayesian network meta-analysis; 3 contributed to the base case network, including 3 LAGHs (lonapegsomatropin, somapacitan, and somatrogon) and daily somatropin. Treatment with lonapegsomatropin was associated with statistically significantly higher annualized height velocity and change from baseline in height SD score (SDS) at week 52 compared to daily somatropin and somapacitan; no other significant differences in these outcomes were found. The change from baseline in average insulin-like growth factor-1 (IGF-1) SDS at week 52 was significantly higher for somatrogon vs all comparators and for lonapegsomatropin vs daily somatropin and somapacitan; average IGF-1 SDS was within normal range in all trials. No significant differences were seen in progression in bone age-to-chronological age ratio or serious adverse events (SAEs). Sensitivity analyses were consistent with the base case. In this network meta-analysis, lonapegsomatropin was the only LAGH associated with better growth outcomes. No significant differences were detected regarding SAEs; other safety outcomes could not be analyzed.

Schlagwörter

Stichwörter der Autor:innen

literature reviewlong-acting growth hormonemeta-analysispediatric growth hormone deficiency

Autor:innen und Institutionen

  • Department of Pediatric Endocrinology, Christliches Kinderhospital, Osnabrueck 49074, Germany.
  • Cencora, Conshohocken, PA 19428, USA.
  • Cencora, Hannover D-30159, Germany.
  • Cencora, London WC2B 4PJ, UK.
  • Ascendis Pharma Inc, Palo Alto, CA 94304, USA.
  • Ascendis Pharma A/S, Hellerup DK-2900, Denmark.

ORCID-Profile: Sarah Cadarette

Förderung

  • Ascendis Pharma A/S

Zitieren

APA

Albers, N., Cadarette, S., Feakins, B., Arregui, M., Ebohon, S., Lai, P., Raveendran, S., Kjelgaard-Hansen, M., Andersen, C., Zhao, C., Smith, A., & Geffner, M. (2025). Long-Acting Growth Hormone for Pediatric Growth Hormone Deficiency. Journal of the Endocrine Society, 9(5). https://doi.org/10.1210/jendso/bvaf040

Vancouver

Albers N, Cadarette S, Feakins B, Arregui M, Ebohon S, Lai P, et al. Long-Acting Growth Hormone for Pediatric Growth Hormone Deficiency. Journal of the Endocrine Society. 2025;9(5). doi:10.1210/jendso/bvaf040

BibTeX
@article{Albers2025,
  author = {Albers, Norbert and Cadarette, Sarah and Feakins, Ben and Arregui, María and Ebohon, Stephen and Lai, Pamela and Raveendran, Subhara and Kjelgaard-Hansen, Mads and Andersen, Christine and Zhao, Carol and Smith, Alden and Geffner, Mitchell},
  title = {Long-Acting Growth Hormone for Pediatric Growth Hormone Deficiency},
  journal = {Journal of the Endocrine Society},
  year = {2025},
  volume = {9},
  number = {5},
  doi = {10.1210/jendso/bvaf040}
}
Kostenlos starten →